WT1 as a novel target antigen for cancer immunotherapy

Current Cancer Drug Targets

Volumn 2, Issue 1, 2002, Pages 45-54

  Oka, Y ^a   Tsuboi, A ^a   Elisseeva, O A ^a   Udaka, K ^b   Sugiyama, H ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; COMPLEMENTARY DNA; GENE PRODUCT; HLA A2 ANTIGEN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN BINDING; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN MOTIF; REVIEW; TUMOR CELL; VACCINATION; WILD TYPE; WT1 GENE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; DRUG DELIVERY SYSTEMS; HUMANS; LEUKEMIA; WT1 PROTEINS;

EID: 0036283517     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009023334088     Document Type: Review

References (46)

1. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes
2. MHC ligands peptide motifs first listing
3. Tumor immunity: Will new keys unlock the door
4. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilm's tumor locus
5. Homozygous deletion in Wilms' tumours of a zinc-finger gene identified by chromosome jumping
6. The Wilms' tumor 1 gene: Oncogene or tumor suppressor gene?
7. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia
8. Aberrant overexpression of the Wilms' tumor gene (WT1) in human leukemia
9. Expression of the Wilms' tumor gene (WT1) in human leukemias
10. Expression of the candidate Wilms' tumor gene, WT1, in human leukemia cells
11. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells
12. Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias
13. Growth inhibition of human leukemic cells by WT1 (Wilms Tumor Gene) antisense oligonucleotides: Implications for the involvement of WT1 in leukemogenesis
14. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells
15. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF)
16. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth
17. Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promotor methylation
18. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product
19. Cancer immunotherapy targeting Wilms' tumor gene WT1 product
20. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination
21. + progenitor cells by cytotoxic T lymphocytes specific for WT1
22. + cytotoxic T-lymphocyte clone specific for WT1 peptide
23. + progenitors and downregulated early in the course of differentiation in vitro
24. + progenitors
25. Efficient induction of peptide-specific cytotoxic T lymohocytes by LPS-activated spleen cells
26. Direct gene transfer into mouse muscle in vivo
27. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization
28. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effort of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantation
29. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
30. Targeting p53 as a General Tumor Antigen
31. Peptides derived from a wild-type murine proto-oncogene C-erbB-2/her2/neu can induce CTL and tumor suppression in syngeneic hosts
32. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immune-gene therapy
33. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL
34. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia
35. Constitutive expression of the Wilms' tumor gene (WT1) in the leukemic cell line U937 blocks parts of the differentiation program
36. Dominance and crypticity of T cell antigenic determinants
37. Processing of self-proteins and its impact on shaping the T cell repertoire, autoimmunity, and immune regulation
38. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by nondominant anchor residues
39. Can antitumor immune responses discriminate between self and nonself?
40. How cytotoxic T cells manage to discriminate nonself from self at the nonapeptide level
41. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gpi00 modified at HLA-a*0201-Binding residues
42. Induction of tumor reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
43. Wilms' tumor gene WT1: Its oncogenic function and clinical application
44. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
45. Immunotherapy of cancer with dendritic-cell-based vaccines
46. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma